Literature DB >> 19882568

Scleral buckle removal associated with pars plana vitrectomy for recurrent retinal detachment.

Tommaso Rossi1, Barbara Boccassini, Mario Iossa, Guido Lesnoni, P Alessandro Mutolo.   

Abstract

PURPOSE: Scleral buckle (SB) removal is rarely performed due to extrusion, infection, or diplopia. We report a series of patients with recurrent retinal detachment (RRD) after primary SB due to new breaks occurring at sites where the presence of a pre-existing SB was judged counterproductive. All patients were treated by means of pars plana vitrectomy (PPV) and SB removal with the sole purpose of achieving a more favorable retinal profile.
METHODS: We retrospectively reviewed all patients undergoing PPV and SB removal for RRD due to new breaks occurring at sites hidden by pre-existing exoplants.
RESULTS: Mean age was 52 years and VA on presentation was 20/620 and 20/216 at latest visit (p<0.01), 23 months of follow-up. On presentation, 3/11 (27%) had a VA better than 20/400 and 1/11 (9%) better than 20/40. At the end of follow-up, 9/11 (81%) and 3/11 (27%) saw better than 20/400 and 20/40 (p<0.05). At the end of follow-up, 8/11 (72%) had an attached retina, 2/11 (18%) had a partially attached retina, and 1/11 (9%) had a total RD. Explanted buckles included 5 silicone sponges and 6 solid silicone rubber elements.
CONCLUSIONS: Although occasionally cumbersome and time-consuming, SB removal may provide a more favorable retinal profile and improve retina-tamponade contact. Larger series are needed to assess if this translates into a significant benefit in the treatment of selected RRD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19882568     DOI: 10.1177/112067210901900624

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  1 in total

1.  The validity and reliability of the Arabic version of the ocular surface disease index (OSDI) questionnaire in a sample of the Gazan population: a study from Palestine.

Authors:  Mohammed Aljarousha; Noor Ezailina Badarudin; Mohd Zulfaezal Che Azemin; Yousef Aljeesh; Abuimara Amer; Muhammad Afzam Shah Abdul Rahim
Journal:  Int Ophthalmol       Date:  2022-09-26       Impact factor: 2.029

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.